$CI

Kates Jamie G sold $268K of CI

Kates Jamie G (Chief Accounting Officer) sold 899 shares of Cigna Group (CI) at $298.61 ($0.27M total) on 2026-06-12.

Original reporting
SEC EDGAR · Kates Jamie G
Published Jun 16, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CI
Neutral
high confidence
Mentioned
$CI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CINeutralLow
01

Why it matters

The disclosure provides a new, company-specific datapoint on insider selling activity, but it does not introduce new operational, financial, or regulatory information.

02

Market read

Traders may monitor for insider selling trends, but the filing alone is unlikely to drive a durable repricing without accompanying fundamental catalysts.

03

What to watch

The article lacks context on total insider holdings, prior sale frequency, and whether other executives are selling/buying around the same period.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-16 (after transaction dated 2026-06-12)

Background

This is an SEC Form 4 insider transaction disclosure for Cigna Group (CI).

Company-level read

Ticker impact

$CINeutralHigh confidence
Context

Cigna Group insider Form 4 shows Chief Accounting Officer Kates Jamie G sold 899 shares at $298.6120 on 2026-06-12.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless part of a broader selling pattern.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a modest share count; it does not include new company fundamentals, guidance, or regulatory/legal developments.

Market effects

Minimal; single-insider sale in a large insurer does not reset sector expectations.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-scheduled liquidity needs; without a 10b5-1 plan, the sale still may not imply negative outlook.

Key entities

  • Cigna Group

    CI, the company whose insider transaction was reported on Form 4.

  • Kates Jamie G

    Chief Accounting Officer reporting an open-market sale of CI shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CIMed

The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities

Cigna Group (CI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities • Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned

$NVOMed

GLP-1 prices are falling but a big change could affect what you pay

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.